BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

908 related articles for article (PubMed ID: 26058962)

  • 1. Taxane-containing regimens for metastatic breast cancer.
    Ghersi D; Willson ML; Chan MM; Simes J; Donoghue E; Wilcken N
    Cochrane Database Syst Rev; 2015 Jun; 2015(6):CD003366. PubMed ID: 26058962
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Taxanes for adjuvant treatment of early breast cancer.
    Willson ML; Burke L; Ferguson T; Ghersi D; Nowak AK; Wilcken N
    Cochrane Database Syst Rev; 2019 Sep; 9(9):CD004421. PubMed ID: 31476253
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Taxane containing regimens for metastatic breast cancer.
    Ghersi D; Wilcken N; Simes J; Donoghue E
    Cochrane Database Syst Rev; 2005 Apr; (2):CD003366. PubMed ID: 15846659
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Taxane containing regimens for metastatic breast cancer.
    Ghersi D; Wilcken N; Simes J; Donoghue E
    Cochrane Database Syst Rev; 2003; (3):CD003366. PubMed ID: 12917963
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trastuzumab-containing regimens for metastatic breast cancer.
    Balduzzi S; Mantarro S; Guarneri V; Tagliabue L; Pistotti V; Moja L; D'Amico R
    Cochrane Database Syst Rev; 2014 Jun; 2014(6):CD006242. PubMed ID: 24919460
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Platinum-containing regimens for metastatic breast cancer.
    Egger SJ; Willson ML; Morgan J; Walker HS; Carrick S; Ghersi D; Wilcken N
    Cochrane Database Syst Rev; 2017 Jun; 6(6):CD003374. PubMed ID: 28643430
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sequencing of anthracyclines and taxanes in neoadjuvant and adjuvant therapy for early breast cancer.
    Zaheed M; Wilcken N; Willson ML; O'Connell DL; Goodwin A
    Cochrane Database Syst Rev; 2019 Feb; 2(2):CD012873. PubMed ID: 30776132
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Taxanes for adjuvant treatment of early breast cancer.
    Ferguson T; Wilcken N; Vagg R; Ghersi D; Nowak AK
    Cochrane Database Syst Rev; 2007 Oct; (4):CD004421. PubMed ID: 17943815
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ovarian suppression for adjuvant treatment of hormone receptor-positive early breast cancer.
    Bui KT; Willson ML; Goel S; Beith J; Goodwin A
    Cochrane Database Syst Rev; 2020 Mar; 3(3):CD013538. PubMed ID: 32141074
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Taxanes for the adjuvant treatment of early breast cancer: systematic review and economic evaluation.
    Ward S; Simpson E; Davis S; Hind D; Rees A; Wilkinson A
    Health Technol Assess; 2007 Oct; 11(40):1-144. PubMed ID: 17903394
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Platinum-containing regimens for triple-negative metastatic breast cancer.
    Egger SJ; Chan MMK; Luo Q; Wilcken N
    Cochrane Database Syst Rev; 2020 Oct; 10(10):CD013750. PubMed ID: 33084020
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer.
    Patel A; Kalachand R; Busschots S; Doherty B; Kapros E; Lawlor D; Hall N; Stordal BK
    Cochrane Database Syst Rev; 2022 Jul; 7(7):CD008766. PubMed ID: 35866378
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fulvestrant for hormone-sensitive metastatic breast cancer.
    Lee CI; Goodwin A; Wilcken N
    Cochrane Database Syst Rev; 2017 Jan; 1(1):CD011093. PubMed ID: 28043088
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Single agent versus combination chemotherapy for metastatic breast cancer.
    Carrick S; Parker S; Wilcken N; Ghersi D; Marzo M; Simes J
    Cochrane Database Syst Rev; 2005 Apr; (2):CD003372. PubMed ID: 15846660
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination versus sequential single agent chemotherapy for metastatic breast cancer.
    Dear RF; McGeechan K; Jenkins MC; Barratt A; Tattersall MH; Wilcken N
    Cochrane Database Syst Rev; 2013 Dec; 2013(12):CD008792. PubMed ID: 24347031
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bisphosphonates and other bone agents for breast cancer.
    O'Carrigan B; Wong MH; Willson ML; Stockler MR; Pavlakis N; Goodwin A
    Cochrane Database Syst Rev; 2017 Oct; 10(10):CD003474. PubMed ID: 29082518
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Platinum containing regimens for metastatic breast cancer.
    Carrick S; Ghersi D; Wilcken N; Simes J
    Cochrane Database Syst Rev; 2004; (3):CD003374. PubMed ID: 15266482
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Platinum containing regimens for metastatic breast cancer.
    Carrick S; Ghersi D; Wilcken N; Simes J
    Cochrane Database Syst Rev; 2004; (2):CD003374. PubMed ID: 15106201
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PARP (Poly ADP-Ribose Polymerase) inhibitors for locally advanced or metastatic breast cancer.
    Taylor AM; Chan DLH; Tio M; Patil SM; Traina TA; Robson ME; Khasraw M
    Cochrane Database Syst Rev; 2021 Apr; 4(4):CD011395. PubMed ID: 33886122
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PI3K/AKT/mTOR inhibitors for advanced or recurrent endometrial cancer.
    Roncolato F; Lindemann K; Willson ML; Martyn J; Mileshkin L
    Cochrane Database Syst Rev; 2019 Oct; 10(10):CD012160. PubMed ID: 31588998
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 46.